Atjaunināt sīkdatņu piekrišanu

E-grāmata: Lyophilized Biologics and Vaccines: Modality-Based Approaches

Edited by , Edited by
  • Formāts: PDF+DRM
  • Izdošanas datums: 19-May-2015
  • Izdevniecība: Springer-Verlag New York Inc.
  • Valoda: eng
  • ISBN-13: 9781493923830
  • Formāts - PDF+DRM
  • Cena: 118,37 €*
  • * ši ir gala cena, t.i., netiek piemērotas nekādas papildus atlaides
  • Ielikt grozā
  • Pievienot vēlmju sarakstam
  • Šī e-grāmata paredzēta tikai personīgai lietošanai. E-grāmatas nav iespējams atgriezt un nauda par iegādātajām e-grāmatām netiek atmaksāta.
  • Formāts: PDF+DRM
  • Izdošanas datums: 19-May-2015
  • Izdevniecība: Springer-Verlag New York Inc.
  • Valoda: eng
  • ISBN-13: 9781493923830

DRM restrictions

  • Kopēšana (kopēt/ievietot):

    nav atļauts

  • Drukāšana:

    nav atļauts

  • Lietošana:

    Digitālo tiesību pārvaldība (Digital Rights Management (DRM))
    Izdevējs ir piegādājis šo grāmatu šifrētā veidā, kas nozīmē, ka jums ir jāinstalē bezmaksas programmatūra, lai to atbloķētu un lasītu. Lai lasītu šo e-grāmatu, jums ir jāizveido Adobe ID. Vairāk informācijas šeit. E-grāmatu var lasīt un lejupielādēt līdz 6 ierīcēm (vienam lietotājam ar vienu un to pašu Adobe ID).

    Nepieciešamā programmatūra
    Lai lasītu šo e-grāmatu mobilajā ierīcē (tālrunī vai planšetdatorā), jums būs jāinstalē šī bezmaksas lietotne: PocketBook Reader (iOS / Android)

    Lai lejupielādētu un lasītu šo e-grāmatu datorā vai Mac datorā, jums ir nepieciešamid Adobe Digital Editions (šī ir bezmaksas lietotne, kas īpaši izstrādāta e-grāmatām. Tā nav tas pats, kas Adobe Reader, kas, iespējams, jau ir jūsu datorā.)

    Jūs nevarat lasīt šo e-grāmatu, izmantojot Amazon Kindle.

This book provides a detailed account of the most recent developments, challenges and solutions to seamlessly advance and launch a lyophilized biologics or vaccine product, based on diverse modalities, ranging from antibodies (e.g.,monoclonal, fused), complex biologics (e.g., antibody drug conjugate, PEGylated proteins), and vaccines (e.g.,recombinant-protein based). The authors adeptly guide the reader through all crucial aspects, from biophysical and chemical stability considerations of proteins, analytical methods, advances in controlled ice nucleation and quality-by-design approaches, alternate drying technology, to latest regulatory, packaging and technology transfer considerations to develop a stable, safe and effective therapeutic protein, vaccine and biotechnology products.

Lyophilized Biologics and Vaccines: Modality-Based Approaches is composed of four sections with a total of 17 chapters. It serves as a reference to all critical assessments and steps from early pre-formulation stages to product launch:

  • Provides recent understanding of heterogeneity of protein environment and selection of appropriate buffer for stabilization of lyophilized formulations
  • Details the latest developments in instrumental analysis and controlled ice nucleation technology
  • Explains in-depth lyophilized (or dehydrated) formulation strategies considering diverse modalities of biologics and vaccines, including plasmid DNA and lipid-based therapeutics
  • Details an exhaustive update on quality-by-design and process analytical technology approaches, illustrated superbly by case studies and FDA perspective
  • Provides the latest detailed account of alternate drying technologies including spray drying, bulk freeze-drying and crystallization, supported exceptionally by case studies
  • Provides a step-by-step guide through critical considerations during process scale-up, technology transfer, packaging and drug delivery device selection, for a successful lyophilization process validation, regulatory submission and product launch

Chapters are written by one or more world-renowned leading authorities from academia, industry or regulatory agencies, whose expertise cover lyophilization of the diverse modalities of biopharmaceuticals. Their contributions are based on the exhaustive review of literature coupled with excellent hands-on experiences in laboratory or GMP setup, making this an exceptional guide to all stages of lyophilized or dehydrated product development.

Part I Lyophilization History and Fundamentals
History of Lyophilization
3(8)
Dushyant Varshney
Manmohan Singh
Heterogeneity of Protein Environments in Frozen Solutions and in the Dried State
11(14)
Maya Salnikova
Dushyant Varshney
Evgenyi Shalaev
Advance Understanding of Buffer Behavior during Lyophilization
25(18)
Cindy Wu
Sheri Shamblin
Dushyant Varshney
Evgenyi Shalaev
Advances in Instrumental Analysis Applied to the Development of Lyophilization Cycles
43(30)
William J. Kessler
Puneet Sharma
Mircea Mujat
New Developments in Controlled Nucleation: Commercializing VERISEQ® Nucleation Technology
73(20)
Joseph Brower
Ron Lee
Eugene Wexler
Steven Finley
Monica Caldwell
Peter Studer
Part II Lyophilized Biologics and Vaccines -- Modality Considerations
Lyophilized Biologics
93(28)
Byeong S. Chang
Michael Reilly
Hana Chang
Lyophilization of Therapeutic Proteins in Vials: Process Scale-Up and Advances in Quality by Design
121(36)
Bingquan (Stuart) Wang
Timothy R. McCoy
Michael J. Pikal
Dushyant Varshney
Advances in Process Analytical Technology in Freeze-Drying
157(22)
Bingquan (Stuart) Wang
Timothy R. McCoy
Process Scale-Up and Optimization of Lyophilized Vaccine Products
179(32)
Jeffrey T. Blue
Jessica R. Sinacola
Akhilesh Bhambhani
Stabilization of Plasmid DNA and Lipid-Based Therapeutics as Dehydrated Formulations
211(46)
Marion dC. Molina
Nicole M. Payton
Thomas J. Anchordoquy
Part III Advances in Alternate Drying
Alternatives to Vial Lyophilization
257(16)
Jim Searles
Mathew Cherian
Spray-Drying of Biopharmaceuticals
273(26)
Grace A. Ledet
Richard A. Graves
Levon A. Bostanian
Tarun K. Mandal
Current Trends and Advances in Bulk Crystallization and Freeze-Drying of Biopharmaceuticals
299(20)
Hiten Gutka
Krishna Prasad
Case Studies and Examples of Biopharmaceutical Modalities Processed by Bulk Crystallization or Bulk Freeze-Drying
319(22)
Hiten Gutka
Krishna Prasad
Part IV Regulatory, Packaging and Technology Transfer Considerations
Lyophilization of Biologics: An FDA Perspective
341(20)
David Awotwe-Otoo
Mansoor A. Khan
Recent Trends in Lyophilized Delivery Devices and Packaging
361(20)
Renaud Janssen
Lyophilization Process Technology Transfer Towards Product Launch
381(18)
Madhav Kamat
Dushyant Varshney
Index 399
Dushyant B. Varshney, Ph. D., has made significant contributions in manufacturing science and technology, tech transfer, product and process development (including lyophilization), quality-by-design and process analytical technologies for biologics, vaccines and small molecules. Having earned his Ph.D. from the University of Iowa, Dr. Varshney has authored several peer-reviewed scientific publications, review articles, and book chapters, and has presented at several international conferences and chaired scientific workshops. He is currently a Director of Manufacturing Assessment, MS&T at Hospira, Inc. He has previously worked at Novartis, Bristol-Myers Squibb, Sanofi and Eli Lilly & Company.

Manmohan Singh, Ph.D., is a well-known expert in the area of vaccine formulations and adjuvant research, and has been working in vaccine R&D for the last 20 years. He has authored over 130 peer reviewed manuscripts, review articles, and book chapters, and has edited five books in this area. Dr. Singh is on the editorial board of 11 International Journals and has collaborated in organizing several international vaccine conferences. Currently, he is the Head of Global Drug Product Development at Novartis Vaccines and Diagnostics in Holly Springs, NC 27540.